Mapping the future for pulmonary fibrosis: Report from the 17th International Colloquium on Lung and Airway Fibrosis

European Respiratory Journal

Volumn 42, Issue 1, 2013, Pages 230-238

  Richeldi, Luca ^a   Collard, Harold R ^b   Du Bois, Roland M ^c   Jenkins, Gisli ^d   Kolb, Martin ^e   Maher, Toby M ^f   Raghu, Ganesh ^g   Vancheri, Carlo ^h   Laurent, Geoffrey J ^i,j  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

^f ROYAL BROMPTON HOSPITAL   (United Kingdom)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF CATANIA   (Italy)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY COLLEGE LONDON   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HISTONE DEACETYLASE; TRANSFORMING GROWTH FACTOR BETA;

CLINICAL FEATURE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MARKER; EXPERIMENTAL MODEL; HUMAN; LUNG ALVEOLUS MACROPHAGE; LUNG FIBROSIS; MEDICAL RESEARCH; MEDICAL SOCIETY; MOLECULAR PATHOLOGY; NONHUMAN; ORGANIZATIONAL DOWNSIZING; ORGANIZATIONAL EFFICIENCY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PHYSICIAN ATTITUDE; PRIORITY JOURNAL; PROFESSIONAL COMPETENCE; PROFESSIONAL KNOWLEDGE; PUBLIC-PRIVATE PARTNERSHIP; PUBLICATION; REVIEW;

BIOMEDICAL RESEARCH; HUMANS; INTERNATIONAL COOPERATION; ITALY; PULMONARY FIBROSIS; PULMONARY MEDICINE; SOCIETIES, MEDICAL;

EID: 84880152731     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00038613     Document Type: Review

References (32)

1. University of Modena and Reggio Emilia. The 17th International Colloquium on Lung and Airways Fibrosis, 2012. http://tv.unimore.it/index.php/29-canali- sp-356/registrazioni-video-sp-746/625-iclaf2012 Date last updated: January 10, 2013. Date last accessed: May 13, 2013.
2. Warburton D, Shi W, Xu B. TGF-b-Smad3 signaling in emphysema and pulmonary fibrosis: an epigenetic aberration of normal development? Am J Physiol Lung Cell Mol Physiol 2013; 304: L83-L85.
3. Huang X, Yang N, Fiore VF, et al. Matrix stiffness-induced myofibroblast differentiation is mediated by intrinsic mechanotransduction. Am J Respir Cell Mol Biol 2012; 47: 340-348.
4. Zhou Y, Huang X, Hecker L, et al. Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental pulmonary fibrosis. J Clin Invest 2013; 123: 1096-1108.
5. Hecker L, Vittal R, Jones T, et al. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009; 15: 1077-1081.
6. King TE Jr, Albera C, Bradford WZ, et al. Effect of interferon-c-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet 2009; 374: 222-228.
7. Maher TM, Wells AU, Laurent GJ. Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms? Eur Respir J 2007; 30: 835-839. (Pubitemid 351194784)
8. Maher TM. Idiopathic pulmonary fibrosis: pathobiology of novel approaches to treatment. Clin Chest Med 2012; 33: 69-83.
9. Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 717-723.
10. Moeller A, Gilpin SE, Ask K, et al. Circulating fibrocytes are an indicator of poor prognosis in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2009; 179: 588-594.
11. Richards TJ, Kaminski N, Gibson KF. Plasma proteins for risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185: 1329-1330.
12. Selman M, Pardo A, Barrera L, et al. Gene expression profiles distinguish idiopathic pulmonary fibrosis from hypersensitivity pneumonitis. Am J Respir Crit Care Med 2006; 173: 188-198. (Pubitemid 43187891)
13. Doyle TJ, Hunninghake GM, Rosas IO. Subclinical interstitial lung disease: why you should care. Am J Respir Crit Care Med 2012; 185: 1147-1153.
14. Rosas IO, Ren P, Avila NA, et al. Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med 2007; 176: 698-705. (Pubitemid 47503078)
15. Rosas IO, Richards TJ, Konishi K, et al. MMP1 and MMP7 as potential peripheral blood biomarkers in idiopathic pulmonary fibrosis. PLoS Med 2008; 5: e93.
16. Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84: 365-369. (Pubitemid 20287410)
17. Wells AU, King AD, Rubens MB, et al. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997; 155: 1367-1375. (Pubitemid 27172785)
18. Wells AU, Desai SR, Rubens MB, et al. Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med 2003; 167: 962-969. (Pubitemid 36408161)
19. Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest 2012; 141: 222-231.
20. Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26: 586-593. (Pubitemid 41448654)
21. Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103: 1209-1215.
22. Schmidt SL, Nambiar AM, Tayob N, et al. Pulmonary function measures predict mortality differently in IPF versus combined pulmonary fibrosis and emphysema. Eur Respir J 2011; 38: 176-183.
23. Cottin V, Nunes H, Mouthon L, et al. Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis Rheum 2011; 63: 295-304.
24. Laurent GJ. Dynamic state of collagen: pathways of collagen degradation in vivo and their possible role in regulation of collagen mass. Am J Physiol 1987; 252: C1-C9.
25. McKleroy W, Lee T-H, Atabai K. Always cleave up your mess: targeting collagen degradation to treat tissue fibrosis. Am J Physiol Lung Cell Mol Physiol 2013 [In press DOI:10.1152/ajplung.00418.2012].
26. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
27. Horowitz JC, Ajayi IO, Kulasekaran P, et al. Survivin expression induced by endothelin-1 promotes myofibroblast resistance to apoptosis. Int J Biochem Cell Biol 2012; 44: 158-169.
28. Patel AS, Lin L, Geyer A, et al. Autophagy in idiopathic pulmonary fibrosis. PLoS One 2012; 7: e41394.
29. Mutlu GM, Budinger GR, Wu M, et al. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-b1 signalling. Thorax 2012; 67: 139-146.
30. Chua F, Gauldie J, Laurent GJ. Pulmonary fibrosis: searching for model answers. Am J Respir Cell Mol Biol 2005; 33: 9-13. (Pubitemid 40961008)
31. Moeller A, Ask K, Warburton D, et al. The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 2008; 40: 362-382. (Pubitemid 351249887)
32. Seok J, Warren HS, Cuenca AG, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110: 3507-3512.